Is skin autofluorescence a marker of metabolic memory in pregnant women with diabetes?

Diabetic Medicine

Volumn 32, Issue 12, 2015, Pages 1575-1579

  Maury, E ^a,b,c   Savel, J ^a   Grouthier, V ^d   Rajaobelina, K ^b,c   Corvo, L ^a   Lorrain, S ^b,c   Gonzalez, C ^a   Gin, H ^a   Barberger Gateau, P ^b,c   Rigalleau, V ^a,b,c  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM   (France)

^d HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; BIOLOGICAL MARKER; FRUCTOSAMINE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ADVANCED GLYCATION END PRODUCT READER; ANALYTICAL EQUIPMENT; ARTICLE; AUTOFLUORESCENCE; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREGNANCY; PREGNANCY DIABETES MELLITUS; SKIN AUTOFLUORESCENCE; BLOOD; DIABETES, GESTATIONAL; FLUORESCENCE; FOREARM; FRANCE; METABOLISM; RECURRENT DISEASE; RISK; SECOND TRIMESTER PREGNANCY; SKIN; SPECTROFLUOROMETRY; THIRD TRIMESTER PREGNANCY; UPREGULATION;

ADULT; BIOMARKERS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; FEMALE; FLUORESCENCE; FOREARM; FRANCE; FRUCTOSAMINE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PREGNANCY; PREGNANCY IN DIABETICS; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; RECURRENCE; RISK; SKIN; SPECTROMETRY, FLUORESCENCE; UP-REGULATION;

EID: 84983161214     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12803     Document Type: Article

References (19)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35(Suppl. 1): S64-71.
2. Omori Y, Jovanovic L. Proposal for the reconsideration of the definition of gestational diabetes. Diabetes Care 2005; 28: 2592-2593.
3. Jovanovic L. Definition, size of the problem, screening and diagnostic criteria: who should be screened, cost-effectiveness, and feasibility of screening. Int J Gynaecol Obstet 2009; 104(Suppl. 1): S17-19.
4. Degenhardt TP, Thorpe SR, Baynes JW. Chemical modification of proteins by methylglyoxal. Cell Mol Biol 1998; 44: 1139-1145.
5. Meerwaldt R, Graaff R, Oomen PHN, Links TP, Jager JJ, Alderson NL et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004; 47: 1324-1330.
6. Genevieve M, Vivot A, Gonzalez C, Raffaitin C, Barberger-Gateau P, Gin H et al. Skin autofluorescence is associated with past glycaemic control and complications in type 1 diabetes mellitus. Diabetes Metab 2013; 39: 349-354.
7. Collège national des gynécologues et obstétriciens français, Société francophone du diabète. [Gestational diabetes]. J Gynecol Obstet Biol Reprod (Paris) 2010; 39 (8 Suppl. 2): S139, S338-342.
8. De Ranitz-Greven WL, Kaasenbrood L, Poucki WK, Hamerling J, Bos DC, Visser GHA et al. Advanced glycation end products, measured as skin autofluorescence, during normal pregnancy and pregnancy complicated by diabetes mellitus. Diabetes Technol Ther 2012; 14: 1134-1139.
9. Capula C, Chiefari E, Vero A, Foti DP, Brunetti A, Vero R. Prevalence and predictors of postpartum glucose intolerance in Italian women with gestational diabetes mellitus. Diabetes Res Clin Pract 2014; 105: 223-230.
10. Maynard JD, Rohrscheib M, Way JF, Nguyen CM, Ediger MN. Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C. Diabetes Care 2007; 30: 1120-1124.
11. Alberico S, Montico M, Barresi V, Monasta L, Businelli C, Soini V et al. The role of gestational diabetes, pre-pregnancy body mass index and gestational weight gain on the risk of newborn macrosomia: results from a prospective multicentre study. BMC Pregnancy Childbirth 2014; 14: 23.
12. Koetsier M, Lutgers HL, de Jonge C, Links TP, Smit AJ, Graaff R. Reference values of skin autofluorescence. Diabetes Technol Ther 2010; 12: 399-403.
13. Toescu V, Nuttall SL, Martin U, Kendall MJ, Dunne F. Oxidative stress and normal pregnancy. Clin Endocrinol (Oxf) 2002; 57: 609-613.
14. Piperi C, Adamopoulos C, Dalagiorgou G, Diamanti-Kandarakis E, Papavassiliou AG. Crosstalk between advanced glycation and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases. J Clin Endocrinol Metab 2012; 97: 2231-2242.
15. Chen M, Bergman RN, Pacini G, Porte D. Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased beta-cell function. J Clin Endocrinol Metab 1985; 60: 13-20.
16. Cohen A, Pieper CF, Brown AJ, Bastian LA. Number of children and risk of metabolic syndrome in women. J Womens Health 2006; 15: 763-773.
17. Guosheng L, Hongmei S, Chuan N, Haiying L, Xiaopeng Z, Xianqiong L. The relationship of serum AGE levels in diabetic mothers with adverse fetal outcome. J Perinatol 2009; 29: 483-488.
18. De Ranitz-Greven WL, Bos DC, Poucki WK, Visser GHA, Beulens JWJ, Biesma DH et al. Advanced glycation end products, measured as skin autofluorescence, at diagnosis in gestational diabetes mellitus compared with normal pregnancy. Diabetes Technol Ther 2012; 14: 43-49.
19. Blaauw J, Smit AJ, van Pampus MG, van Doormaal JJ, Aarnoudse JG, Rakhorst G et al. Skin autofluorescence, a marker of advanced glycation end products and oxidative stress, is increased in recently preeclamptic women. Am J Obstet Gynecol 2006; 195: 717-722.